Quay Pharma Ltd
Dormant Company
Quay Pharma Ltd contacts: address, phone, fax, email, website, shedule
Address: Quay House 28 Parkway Deeside Industrial Park CH5 2NS Deeside
Phone: +44-1239 1386718
Fax: +44-1239 1386718
Email: n\a
Website: n\a
Shedule:
Incorrect data or we want add more details informations for "Quay Pharma Ltd"? - send email to us!
Registration data Quay Pharma Ltd
Register date: 2006-09-13
Register number: 05934226
Type of company: Private Limited Company
Get full report form global database UK for Quay Pharma LtdOwner, director, manager of Quay Pharma Ltd
Professor Michael Henry Rubinstein Director. Address: 28 Parkway, Deeside Industrial Park, Deeside, Clwyd, CH5 2NS. DoB: October 1944, British
David Hugh Patterson Director. Address: 28 Parkway, Deeside Industrial Park, Deeside, Clwyd, CH5 2NS. DoB: September 1965, British
Jobs in Quay Pharma Ltd vacancies. Career and practice on Quay Pharma Ltd. Working and traineeship
Sorry, now on Quay Pharma Ltd all vacancies is closed.
Responds for Quay Pharma Ltd on FaceBook
Read more comments for Quay Pharma Ltd. Leave a respond Quay Pharma Ltd in social networks. Quay Pharma Ltd on Facebook and Google+, LinkedIn, MySpaceAddress Quay Pharma Ltd on google map
Other similar UK companies as Quay Pharma Ltd: Hatsech Limited | Kudox Na Limited | Qrbay Limited | Infinet Limited | Central Heating World Ltd
Quay Pharma Ltd can be contacted at Deeside at Quay House 28 Parkway. Anyone can find the company using the area code - CH5 2NS. The firm has been operating on the English market for ten years. The firm is registered under the number 05934226 and company's public status is active. The firm SIC and NACE codes are 99999 which means Dormant Company. Quay Pharma Limited reported its account information up till 2015/05/31. The company's most recent annual return information was submitted on 2015/09/13.
This firm owes its well established position on the market and permanent growth to a group of two directors, who are Professor Michael Henry Rubinstein and David Hugh Patterson, who have been overseeing the firm since 2006.